Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral HLD-200 met the primary endpoint of improving ADHD-RS-IV to...